Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

3 clinical studies listed.

Filters:

Adalimumab

Tundra lists 3 Adalimumab clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

COMPLETED

NCT05909852

A Study Comparing the Pharmacokinetics (PK) of ABP 501 40 mg/0.4 mL (ABP 501-HCF) and ABP 501 40 mg/0.8 ml (ABP 501-LCF) in Healthy Adult Participants

To determine the pharmacokinetic (PK) comparability of ABP 501 40 mg/0.4 mL (ABP 501-HCF) compared to ABP 501 40 mg/0.8 mL (ABP 501-LCF) following single-dose subcutaneous (SC) injection, as assessed principally by area under the serum concentration-time curve (AUC) from time 0 extrapolated to infinity (AUCinf) and maximum observed serum concentration (Cmax) in healthy adult participants.

Gender: All

Ages: 18 Years - 55 Years

Updated: 2026-06-25

3 states

Adalimumab
RECRUITING

NCT05590416

A Study of Adalimumab in Acute Vogt-Koyanagi-Harada Disease

This project is designed to test the hypothesis that adalimumab is clinically useful for patients with acuta Vogt-Koyanagi-Harada disease

Gender: All

Ages: 18 Years - 70 Years

Updated: 2024-07-03

1 state

Vogt-Koyanagi-Harada Disease
Adalimumab
RECRUITING

NCT04300686

A Pilot Study in Severe Patients With Takayasu Arteritis.

Takayasu arteritis (TAK) is a rare chronic inflammatory arteritis, which lacks an effective well-accepted intervention strategy. We classify TAK patients into 3 levels, including mild, moderate, and severe. And the biological agents tocilizumab and adalimumab are randomly prescribed in severe patients, to find out the relatively better treatment strategy, facilitating better intervention strategy in severe TAK patients.

Gender: All

Ages: 14 Years - 100 Years

Updated: 2021-08-10

1 state

Takayasu Arteritis
Tocilizumab
Adalimumab
+1